Treatment of lung metastasis from renal cell carcinoma with lymphokine-activated killer cells and interleukin-2.

首先探讨了淋巴因子激活杀伤细胞（LAK）的诱导条件。培养基中血清浓度、1、2、5%对LAK活性无影响。培养瓶中外周血淋巴细胞的最佳密度为2 × 10^6/ml，重组白细胞介素-2 （<@2r<@D2IL-2）生成LAK细胞的最有效浓度为3u/ml。对Daudi细胞的细胞毒性在培养第2天出现，第3天达到峰值。直立培养和滚动培养诱导的LAK活性无显著差异。1例肾细胞癌肺转移患者采用LAK细胞和<@2r<@D2IL-2治疗。LAK细胞和<@D2r@>D2IL-2在14个月内给予11次，前2次静脉注射，9次经支气管动脉注射。注射LAK细胞总数为16.1x10<@D19@>个D1细胞。诱导LAK活性逐渐降低，在第6次处理时达到最低。从第6次治疗开始，在给予LAK细胞前一天进行血浆交换。诱导LAK活性较第7次处理恢复。尽管这些治疗，转移灶的大小逐渐增加。

The conditions to induce lymphokine-activated killer (LAK) cells were investigated at first. Concentrations of serum in culture media, 1, 2 and 5% had no effect on induced LAK activity. The best density of peripheral blood lymphocytes in culture bottle was 2x10^6/ml, and the most effective concentration of recombinant interleukin-2 (<@2r<@D2IL-2) to generate LAK cells was 3u/ml. Cytotoxicity against Daudi cell appeared on the second day of culture and reached a peak on the third day. There was no difference in induced LAK activity between standing and rolling culture.One patient with lung metastasis from renal cell carcinoma was treated with LAK cells and <@2r<@D2IL-2. LAK cells and <@D2r@>D2IL-2 were administered 11 times during 14 months, the first 2 times intravenously and 9 times via bronchial artery. The total number of LAK cells injected was 16.1x10<@D19@>D1 cells. Induced LAK activities gradually decreased and reached minimum at 6th treatment. From the 6th treatment plasma exchange was performed the day before administration of LAK cells. Induced LAK activities recovered from the 7th treatment. Despite these treatments the size of the metastatic lesion gradually increased.